Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.medidd.2020.100039 http://scihub22266oqcxt.onion/10.1016/j.medidd.2020.100039 32313880!7166201!32313880     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Drug+Discov 2020 ; 6 (ä): 100039 Nephropedia Template TP {{tp|p=32313880|t=2020. PAK1-blockers: Potential Therapeutics against COVID-19 |pdf=|usr=}}{{32313880}} gab.com Text PAK1-blockers: Potential Therapeutics against COVID-19 JO: Med Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=32313880 #FOAvip PAK1 (RAC/CDC42-activated kinase 1) is the major "pathogenic" kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pasteur who developed a vaccine against rabies in 1885, in general a series of "specific" vaccines have been used for treatment of viral infection, mainly because the majority of pre-existing antibiotics are either anti-bacterial or anti-fungal, thereby being ineffective against viruses in general. However, it takes 12-18?months till the effective vaccine becomes available. Until then ventilator (O(2) supplier) would be the most common tool for saving the life of COVID-19 patients. Thus, as alternative potentially more direct "broad-spectrum" signalling mechanism-based COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here. Twit Text FOAVip PAK1-blockers: Potential Therapeutics against COVID-19 ????Med Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=32313880 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32313880 #FOAvip English Wikipedia <ref>{{Cite pmid|32313880}}</ref> PAK1-blockers: Potential Therapeutics against COVID-19 #MMPMID32313880 Maruta H; He H Med Drug Discov 2020[Jun]; 6 (ä): 100039 PMID32313880show ga PAK1 (RAC/CDC42-activated kinase 1) is the major "pathogenic" kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pasteur who developed a vaccine against rabies in 1885, in general a series of "specific" vaccines have been used for treatment of viral infection, mainly because the majority of pre-existing antibiotics are either anti-bacterial or anti-fungal, thereby being ineffective against viruses in general. However, it takes 12-18?months till the effective vaccine becomes available. Until then ventilator (O(2) supplier) would be the most common tool for saving the life of COVID-19 patients. Thus, as alternative potentially more direct "broad-spectrum" signalling mechanism-based COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here. äPAK1-blockers: Potential Therapeutics against COVID-19 (epmc).pdf DeepDyve Pubget Overpricing